Literature DB >> 2328758

Effects of DM-9384 in a model of amnesia based on animals with GABAergic neuronal dysfunctions.

T Nabeshima1, Y Noda, K Tohyama, J Itoh, T Kameyama.   

Abstract

The effects of N-(2,6-dimethyl-phenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide (DM-9384), a cyclic derivative of GABA, were investigated and compared with those of aniracetam in an animal model of amnesia, using a passive avoidance task with animals that have GABAergic neuronal dysfunctions. Pre- and post-training administration of DM-9384 and aniracetam ameliorated bicuculline-induced amnesia, as indicated by parameters such as % retention and step-down latency. DM-9384 ameliorated picrotoxin-induced amnesia when administered pre-training, but not when administered post-training. Aniracetam failed to improve the picrotoxin-induced amnesia. DM-9384 displaced [3H]muscimol binding to GABAA receptors (-log IC50 = 8.07 M; Hill value = 0.23 +/- 0.04), but failed to displace about 20% of the specific muscimol binding, whereas aniracetam showed only a weak effect (-log IC50 = 3.63 M; Hill value = 0.37 +/- 0.06). From these results, it appears that DM-9384 ameliorated the GABA antagonist-induced amnesia by interacting with some GABAA receptors directly and/or indirectly.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2328758     DOI: 10.1016/0014-2999(90)90469-m

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

Review 1.  Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part II.

Authors:  M Sarter; J Hagan; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I.

Authors:  M Sarter; J Hagan; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Evidence for an in vivo and in vitro modulation of endogenous cortical GABA release by alpha-glycerylphosphorylcholine.

Authors:  L Ferraro; S Tanganelli; L Marani; C Bianchi; L Beani; A Siniscalchi
Journal:  Neurochem Res       Date:  1996-05       Impact factor: 3.996

4.  Improvement by nefiracetam of beta-amyloid-(1-42)-induced learning and memory impairments in rats.

Authors:  K Yamada; T Tanaka; T Mamiya; T Shiotani; T Kameyama; T Nabeshima
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

Review 5.  Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders.

Authors:  C R Lee; P Benfield
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

6.  Nefiracetam enhances acetylcholine outflow from the frontal cortex: in vivo microdialysis study in the rat.

Authors:  S Kawajiri; K Taniguchi; T Sakurai; T Yamasaki
Journal:  J Neural Transm Gen Sect       Date:  1994

7.  Reversal effect of DM-9384 on scopolamine-induced acetylcholine depletion in certain regions of the mouse brain.

Authors:  E Abe
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

8.  Effects of nefiracetam, a novel pyrrolidone derivative, on brain monoamine metabolisms in mice.

Authors:  E Abe; S Murai; H Saito; Y Masuda; T Itoh
Journal:  J Neural Transm Gen Sect       Date:  1992

9.  Effects of nefiracetam, DM-9384 on amnesia and decrease in choline acetyltransferase activity induced by cycloheximide.

Authors:  T Shiotani; K Tohyama; K Murase; S Ishihara; T Kameyama; T Yamasaki; S Hatanaka; H Kojima; Y Takasu; T Nabeshima
Journal:  J Neural Transm Gen Sect       Date:  1992

10.  Effects of nefiracetam on deficits in active avoidance response and hippocampal cholinergic and monoaminergic dysfunctions induced by AF64A in mice.

Authors:  E Abe; S Murai; H Saito; Y Masuda; Y Takasu; T Shiotani; H Tachizawa; T Itoh
Journal:  J Neural Transm Gen Sect       Date:  1994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.